Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata

• Uterine fibroids Uterine leiomyomas or fibroids are one of the most common conditions affecting women of reproductive age. They account for approximately a third of all hysterectomies performed. Symptoms often attributed to uterine leiomyomas include excessive menstrual bleeding, dysmenorrhea, pelvic pain, and so called "bulk symptoms," or symptoms related to pressure on adjacent organs such as ureteral obstruction, urinary frequency and urgency, rectal pressure, pelvic pressure and increasing abdominal girth. Current treatment for symptomatic uterine fibroids includes hysterectomy, myomectomy and uterine fibroid embolization.
• Lower urinary tract symptoms Although, urinary symptoms like frequency, urgency, incontinence, and voiding dysfunction are often attributed to fibroids, the relationship between fibroids and lower urinary tract symptoms (LUTS) has been poorly studied. The public health burden of fibroids has been studied before and after radical hysterectomy, supracervical hysterectomy, and total abdominal hysterectomy.(1-3) What is missing in the literature is a comparison of traditional and non-traditional surgical fibroid techniques in a prospective fashion. Moreover, there are no studies evaluating the relationship between anatomic factors like uterine size or fibroid number or location and the presence of LUTS.

Inclusion criteria

• Patients who are at least 18 years of age,
• Vaginal bleeding secondary to anatomic uterine leiomyomas confirmed at the Cleveland Clinic Fibroid and Menstrual Disorders Center,
• Patients complaining of mass effect symptoms due to fibroids, and
• Patients undergoing either hysterectomy, myomectomy, or uterine artery embolization

Exclusion criteria

• Patients who are pregnant, or
• Diagnosis of solitary or multiple intracavitary fibroids without subserosal or intramural leiomyomas present, or
• Prior or interval anti-incontinence procedure, or
• Patients with a urinary tract infection, or
• Patients taking anti-cholinergic medications, or
• Presence of an adnexal mass, or
• Unable or unwilling to complete a follow up survey at six months following treatment